登录 注册 会员服务 联系我们

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma

  • Published:2019-02 Issue: Volume:442 Page:453-463
  • ISSN:0304-3835
  • Container-title:Cancer Letters
  • language:en
  • Short-container-title:Cancer Letters

Author:

Brummer Christina,Faerber Stephanie,Bruss Christina,Blank Christian,Lacroix Ruben,Haferkamp Sebastian,Herr Wolfgang,Kreutz Marina,Renner Kathrin

Funder

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference67 articles.

1. BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

2. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

3. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N. Engl. J. Med.,2012

4. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat. Rev. Clin. Oncol.,2017

5. Combination treatment of patients with BRAF-mutant melanoma: a new standard of care;Simeone;BioDrugs Clin. Immunother. Biopharm. Gene Ther.,2017

Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3